

Project Title	Researcher	Institution	Amount Pledged
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors	Nai-Kong V. Cheung MD, PhD & Ellen Basu, MD, PhD	Memorial Sloan Kettering Cancer Center	\$1,850,000
GMP Manufacture and Clinical Testing of an Hu3F8 Bi-Specific Antibody (Turbo 3F8)	Nai-Kong V. CheungMD, PhD	Memorial Sloan Kettering Cancer Center	\$1,873,000
MIBG Trial	Shakeel Modak, MD	Memorial Sloan Kettering Cancer Center	\$40,000
Combination of Cell-Mediated and Antibody-Mediated Immunotherapy for High-Risk Neuroblastoma: Phase I Study of Haploidentical Natural Killer Cells plus Humanized 3F8	Shakeel Modak, MD	Memorial Sloan Kettering Cancer Center	\$700,000
Bivalent Vaccine Plus Beta-Glucan for High-Risk Neuroblastoma in First Remission	Brian H. Kushner,MD	Memorial Sloan Kettering Cancer Center	\$300,000
Reduced Dose Radiotherapy Trial	Suzanne Wolden, MD	Memorial Sloan Kettering Cancer Center	\$5,000
Molecular Annotation for Treatment of Childhood Cancers (MATCH) Trial: Neuroblastoma	John Maris, MD & Yael Mosse, MD	Children’s Hospital of Philadelphia (CHOP)	\$400,000
Molecular Annotation for Treatment of Childhood Cancers (MATCH) Trial: Neuroblastoma	Wing Leung, MD, PhD	St. Jude Children’s Research Hospital	\$45,000
New Approaches to Neuroblastoma Therapy (NANT)	Various	Consortium of Leading Hospitals	\$125,000
The John K. Bartosz Memorial Fellowship in Pediatric Immunotherapy		Memorial Sloan Kettering Cancer Center	\$298,380
Combination Immunotherapy with Targeted Radiotherapy in Children with Neuroblastoma	Juliet Gray, MD; Paul Sondel MD, PhD;Holger Lode, MD; Mark Gaze, MD	University Hospital London, University Hospital Southampton UK, University of Wisconsin, Madison, University Medicine, Greifswald, Germany	\$145,000
Prevention of Ototoxixty in Children with Neuroblastoma (Reduce Cis-platin Hearing Loss with Enols)	Richard M. Lopachin, MD	Montefiore Medical Center	\$175,000
Novel Immunotherapy Combinations with Dinutuximab Phase I & II Trials	Araz Marachelian, MD	Children's Hospital of Los Angeles	\$300,000
Nurse Navigator as part of the Nepenthe Trial	John Maris, MD & Yael Mosse, MD	Children's Hospital of Philadelphia (CHOP)	\$320,000
Phase I Trial of IL15/IL15 Receptor Alpha-Fc Complex for Post-Therapy Lymphopenia in Children	Shakeel Modak, MD	Memorial Sloan Kettering Cancer Center	\$617,400
Neuroblastoma Bivalent Vaccine Trial	Brian H. Kushner,MD	Memorial Sloan Kettering Cancer Center	\$5,656,000
Transatlantic Integration Targeting ALK in Neuroblastoma	Lucas Moreno, MD	Various	\$200,000
Analysis to Identify Markers of Poor Survival in High Risk Neuroblastoma	Lucas Moreno, MD	Various	\$75,000
Prevention of Cisplatin-Induced Hearing Loss with a Novel Acetophenone	Daniel Weiser, MD	Montefiore Medical Center	\$766,190
Novel Anti-B7H3 and Anti-GD2 Immunotherapy Phase I	Araz Marachelian, MD and Shahab Asgharzadeh, MD	Children's Hospital of Los Angeles	\$400,000
NANT Clinical Trial for Enhanced NK Cells in Treating Neuroblastoma	Araz Marachelian, MD	Children's Hospital of Los Angeles	\$45,000
Enhancing the Efficacy of GD2 Cancer Vaccine in High Risk Neuroblastoma	Nai-Kong V. Cheung, MD, PhD	Memorial Sloan Kettering Cancer Center	\$500,000
Neuroblastoma Clinical Trials Research Program Managers	John Maris, MD	Children’s Hospital of Philadelphia	\$180,000
NANT 2021-01 Phase II STING Trial	Araz Marachelian, MD	Children’s Hospital of Los Angeles	\$450,000
B7H3 CAR T Cell Clinical Trial	Robbie Majzner, MD	Dana Farber Cancer Institute	\$1,200,000
INV724 Bispecific mAb Pharmacokinetic-Pharmacodynamic Modeling to Optimize in Vivo Anti-Neuroblastoma Efficacy	Paul Sondel, MD	University of Wisconsin School of Medicine and Public Health	\$250,000